You are here: Home > News Centre > Corporate News

Corporate News

New UK-China biotech collaboration to develop shingles vaccine


Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of

 China’s CanSino Biologics in collaboration focused on herpes zoster.


11.png1.png



Oxford, UK and Tianjin, China – 14th September 2018 – FOR IMMEDIATE RELEASE


Vaccitech Limited, a UK-based company developing products to treat and prevent multiple 

infectious diseases and cancer, and CanSino Biologics Inc, a China-based vaccine company 

focused on prophylactic and therapeutic vaccines, are starting a new collaboration to develop a 

new vaccine approach to prevent shingles (herpes zoster).


The two companies have signed a Master Collaboration Agreement and initiated their first 

co-development project under that agreement. Preclinical validation work has already been 

completed by Vaccitech and Oxford University’s Jenner Institute. GMP manufacturing will be 

performed by CanSinoBIO at their manufacturing facilities in Tianjin, China. Onward 

development will be joint, with clinical studies to be conducted at sites in both the UK 

and China. 


The companies also plan to explore additional collaborations, combining Vaccitech’s expertise 

in the research and development of non-replicating viral vaccines with the advanced 

manufacturing and development capabilities of CanSinoBIO, which has already achieved NDA 

approval for emergency use and national stockpile for its adenoviral vector-based Ebola 

vaccine in China. Vaccitech has development programmes ongoing in influenza, human 

papillomavirus, chronic hepatitis B and cancer.  



Tom Evans MD, CEO of Vaccitech, said:“We are thrilled to be working with one of the most 

advanced manufacturing and vaccine development groups in Asia, and to have such a strong 

partner in China,”


Xuefeng Yu PhD, Chairman & CEO of CanSinoBIO, added: “This partnership allows us to speed 

up new vaccine development by leveraging strengths from both parties. We are pleased to 

collaborate with one of the world’s best vaccine research and development teams.”


                                                          ENDS


About Vaccitech


Vaccitech uses clinically validated non-replicating viral vectors for the prophylaxis and 

treatment of conditions in which the induction of T cells, along with antibodies, are 

critical for prevention or control. Vaccitech (www.vaccitech.co.uk) is a clinical stage 

vaccine company originating from the University of Oxford’s Jenner Institute, one of 

the oldest and most renowned vaccine research centres in the world. The founders of 

the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor 

Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills 

with regulatory and manufacturing experience. The management team has decades of 

experience in the development of vaccine and therapeutic products.


About CanSinoBIO

CanSinoBIO (www.cansinotech.com) is a fully integrated vaccine company dedicated to 

develop, manufacture and commercialize high quality, innovative vaccines. Founded in the 

Tianjin Economic and Technological Development Area (TEDA) in 2009, CanSinoBIO’s 

founders formed a superb team of scientists and managers who had previously held senior 

management and technical positions at many of the world’s leading pharmaceutical 

companies. CanSinoBIO has established a robust vaccine pipeline and multiple platform 

technologies including the viral vector based vaccine development platform.